5 U.S. Large-Caps Facing Declining Revenue

Loading...
Loading...
Running a multi-billion dollar company is not easy. With it, comes the scrutiny of shareholders over performance metrics such as revenue growth. Of the five companies on our list today that have lagged in growing its sales, four have also seen a drop in share price.

Exxon Mobil Corp. XOM - $83.25

Oil & Gas Refining and Marketing
Exxon Mobil Corporation is an energy company engaged in the exploration and production of crude oil and natural gas. The Company also manufactures and markets petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and a variety of specialty products. Exxon's projects include the Kearl project, Heidelberg project, the Point Thomson project, the Hadrian South project, the Lucius project, the Chirag Oil project, the Tapis Enhanced Oil Recovery project, the Damar project, and the Barzan project, among others.
  • Market Cap: $354,056,249,997
  • Revenues (LTM): $357,103,000,000
  • Revenue Growth (Y/Y): -6.4%
  • Price Change (1 year): -17.6%

Pfizer Inc. PFE - $33.63

Pharmaceuticals
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development and manufacture of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP).
  • Market Cap: $210,777,041,807
  • Revenues (LTM): $49,116,000,000
  • Revenue Growth (Y/Y): -3.8%
  • Price Change (1 year): +16.8%
Click here
to continue reading about the 5 U.S. large-caps facing declining revenue...
Loading...
Loading...
Posted In: Long IdeasTrading Ideas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...